Therapeutic innovation

CARBALIVE: Clinical evaluation of carbons of controlled porosity as a new therapeutic for the treatment of liver cirrhosis and non-alcoholic fatty liver disease

The CARBALIVE Consortium has developed a novel, safe and cheap nanoporous carbon that modulates the effects of bacterial translocation in animal models of liver disease. Feasibility studies have demonstrated that this product advances the current state-of-the-art and is ready for validation through clinical trials. Investigation on the safety and efficacy of this novel nanoporous carbon has been performed in patients with fatty liver disease and cirrhosis. Exploitation of the results of the CARBALIVE project will support the continued development of this material through additional private and public sector investment. The use of this innovative therapy is expected to reduce the economic burden of the disease in Europe, improve survival, enhance the quality of life and facilitate sustainable employment for chronically ill patients.

Quick links


This study received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 634579.